Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has provided an update.
Eupraxia Pharmaceuticals has announced positive results from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis. The trial showed significant improvements in symptom relief and tissue health, particularly in Cohort 6, with no serious adverse events reported. The data suggests that higher doses and increased esophageal coverage of EP-104GI lead to better outcomes, encouraging further exploration of its potential benefits.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that specializes in precision local drug delivery. The company focuses on developing treatments for inflammatory-mediated diseases, such as eosinophilic esophagitis, which causes pain and difficulty swallowing due to white blood cells becoming trapped in the esophagus.
YTD Price Performance: 19.51%
Average Trading Volume: 23,298
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$192.9M
See more insights into EPRX stock on TipRanks’ Stock Analysis page.